Lexotan Drug Interactions

Pharmacokinetic Drug-Drug Interaction (DDI): There is a possibility that compounds which inhibit key oxidative hepatic enzymes may enhance the activity of benzodiazepines.
Co-administration of cimetidine, a multi-CYP inhibitor, and possibly propranolol may prolong the elimination half-life of bromazepam through a substantially reduced clearance (with cimetidine: reduction by 50%). Combined administration with fluvoxamine, an inhibitor of CYP1A2, results in significantly increased bromazepam exposure (AUC, 2.4-fold) and elimination half-life (1.9-fold).
Bromazepam did not affect antipyrine metabolism, which is a surrogate marker for CYP1A2, CYP2B6, CYP2C and CYP3A activity. Furthermore, bromazepam did not induce major CYP450 isozymes in vitro at the level of mRNA; also it did not activate nuclear hormone receptors. Therefore, bromazepam is unlikely to cause pharmacokinetic drug-drug interactions based on CYP450 induction.
Pharmacodynamic Drug-Drug Interaction (DDI): Enhanced side effects such as sedation and cardio-respiratory depression may also occur when bromazepam is co-administered with any centrally acting depressants including alcohol. Alcohol should be avoided in patients receiving bromazepam (see General under Precautions).
See Overdosage for warning of other central nervous system depressants, including alcohol.
In the case of narcotic analgesics, enhancement of euphoria may also occur, leading to an increase in drug dependence.